Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/WCO.0000000000000929 http://scihub22266oqcxt.onion/10.1097/WCO.0000000000000929 33709979!ä!33709979 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Neurol 2021 ; 34 (3): 322-328 Nephropedia Template TP {{tp|p=33709979|t=2021. Vaccinations in multiple sclerosis patients receiving disease-modifying drugs |pdf=|usr=}}{{33709979}} gab.com Text Vaccinations in multiple sclerosis patients receiving disease-modifying drugs JO: Curr Opin Neurol http://www.kidney.de/pget.php?&tw=1&pmid=33709979 #FOAvip PURPOSE OF REVIEW: This review focuses on new evidence supporting the global immunization strategy for multiple sclerosis (MS) patients receiving disease-modifying drugs (DMDs), including the recently available vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. RECENT FINDINGS: New data strengthen the evidence against a causal link between MS and vaccination. Recent consensus statements agree on the need to start vaccination early. Timings for vaccine administration should be adjusted to ensure safety and optimize vaccine responses, given the potential interference of DMDs. Patients treated with Ocrelizumab (and potentially other B-cell depleting therapies) are at risk of diminished immunogenicity to vaccines. This has relevant implications for the upcoming vaccination against SARS-CoV-2. SUMMARY: An early assessment and immunization of MS patients allows optimizing vaccine responses and avoiding potential interference with treatment plans. Vaccinations are safe and effective but some specific considerations should be followed when vaccinating before, during, and after receiving immunotherapy. A time-window for vaccination taking into account the kinetics of B cell repopulation could potentially improve vaccine responses. Further understanding of SARS-CoV-2 vaccine response dynamics in MS patients under specific therapies will be key for defining the best vaccination strategy. Twit Text FOAVip Vaccinations in multiple sclerosis patients receiving disease-modifying drugs ????Curr Opin Neurol http://www.kidney.de/pget.php?&tw=1&pmid=33709979 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33709979 #FOAvip English Wikipedia <ref>{{Cite pmid|33709979}}</ref> Vaccinations in multiple sclerosis patients receiving disease-modifying drugs #MMPMID33709979 Otero-Romero S; Ascherio A; Lebrun-Frenay C Curr Opin Neurol 2021[Jun]; 34 (3): 322-328 PMID33709979show ga PURPOSE OF REVIEW: This review focuses on new evidence supporting the global immunization strategy for multiple sclerosis (MS) patients receiving disease-modifying drugs (DMDs), including the recently available vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. RECENT FINDINGS: New data strengthen the evidence against a causal link between MS and vaccination. Recent consensus statements agree on the need to start vaccination early. Timings for vaccine administration should be adjusted to ensure safety and optimize vaccine responses, given the potential interference of DMDs. Patients treated with Ocrelizumab (and potentially other B-cell depleting therapies) are at risk of diminished immunogenicity to vaccines. This has relevant implications for the upcoming vaccination against SARS-CoV-2. SUMMARY: An early assessment and immunization of MS patients allows optimizing vaccine responses and avoiding potential interference with treatment plans. Vaccinations are safe and effective but some specific considerations should be followed when vaccinating before, during, and after receiving immunotherapy. A time-window for vaccination taking into account the kinetics of B cell repopulation could potentially improve vaccine responses. Further understanding of SARS-CoV-2 vaccine response dynamics in MS patients under specific therapies will be key for defining the best vaccination strategy. |Antirheumatic Agents/adverse effects/*therapeutic use[MESH] |COVID-19 Vaccines/therapeutic use[MESH] |Humans[MESH] |Immunization Programs/*organization & administration[MESH] |Immunotherapy/adverse effects/methods[MESH] |Multiple Sclerosis/*drug therapy/*immunology[MESH] |Vaccination[MESH]Vaccinations in multiple sclerosis patients receiving disease-modifyin(epmc).pdf DeepDyve Pubget Overpricing